ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $72,000 | -77.7% | 10,511 | -48.7% | 0.00% | -100.0% |
Q4 2022 | $322,922 | -80.7% | 20,503 | -80.7% | 0.00% | -80.0% |
Q3 2022 | $1,670,000 | -53.8% | 106,147 | -49.4% | 0.01% | -54.5% |
Q1 2022 | $3,614,000 | -46.7% | 209,636 | -55.1% | 0.01% | -52.2% |
Q4 2021 | $6,781,000 | +132.8% | 466,400 | +188.2% | 0.02% | +91.7% |
Q3 2021 | $2,913,000 | +7.4% | 161,843 | +4.8% | 0.01% | -7.7% |
Q2 2021 | $2,712,000 | +16.4% | 154,420 | -51.0% | 0.01% | -23.5% |
Q4 2018 | $2,329,000 | -72.8% | 315,167 | -46.6% | 0.02% | -56.4% |
Q3 2018 | $8,567,000 | -38.7% | 590,000 | -15.7% | 0.04% | -38.1% |
Q2 2018 | $13,981,000 | -19.1% | 700,111 | -29.0% | 0.06% | -12.5% |
Q1 2018 | $17,274,000 | -24.5% | 985,976 | +6.3% | 0.07% | 0.0% |
Q4 2017 | $22,882,000 | +90.0% | 927,917 | +98.9% | 0.07% | +53.2% |
Q3 2017 | $12,042,000 | +5.7% | 466,577 | +11.1% | 0.05% | 0.0% |
Q2 2017 | $11,390,000 | -4.2% | 420,000 | +5.3% | 0.05% | -14.5% |
Q1 2017 | $11,891,000 | +25.2% | 398,750 | +13.9% | 0.06% | +7.8% |
Q4 2016 | $9,499,000 | +273.8% | 350,000 | +252.8% | 0.05% | +240.0% |
Q3 2016 | $2,541,000 | – | 99,202 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |